UK’s National Institute for Clinical Excellence (NICE) To Re-evaluate GlaxoSmithKline’s Tyverb Cancer Drug

LONDON (Reuters) - Britain's drug funding watchdog NICE said on Thursday patients taking GlaxoSmithKline's breast cancer pill Tyverb can continue with the drug while it assesses its use in advanced cases compared with Roche's Herceptin.